<DOC>
	<DOCNO>NCT01882543</DOCNO>
	<brief_summary>The primary objective study evaluate effect 6 week treatment daily administration AQX-1125 compare placebo average daily pain subject interstitial cystitis/bladder pain syndrome ( IC/BPS ) , treatment , use standardize 11-point numerical rating scale ( NRS ) pain score record electronic diary</brief_summary>
	<brief_title>Efficacy Safety AQX-1125 IC/BPS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Be female , ≥18 ≤75 year age consistently symptoms bladder pain addition urinary urgency and/or urinary frequency 12 month Have diagnosis interstitial cystitis &gt; 6 month ( pain least 12 month ) ≤15 year Have average daily pain score least 5 10 11point NRS pain scale 7 day prior baseline Have undergone cystoscopy document visible sign bladder bleeding , lesion glomerulation within last 36 month prior baseline . Subjects child bear potential , must agree avoid pregnancy use medically acceptable method contraception screen visit throughout study . Must capable void independently Pelvic floor pain ( &gt; 5 10 11point NRS pain scale follow pelvic pain assessment ) Have body mass index [ BMI ] &lt; 18 kg/m2 &gt; 39 kg/m2 Have urinary tract infection include bacterial cystitis within past 30 day . Have great 1+ hematuria dipstick test screen unknown cause History previous procedure ( ) ( augmentation cystoplasty , cystectomy , cystolysis ) affect bladder function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Interstitial cystitis</keyword>
	<keyword>Bladder pain syndrome</keyword>
	<keyword>IC/BPS</keyword>
	<keyword>AQX-1125</keyword>
	<keyword>SHIP1</keyword>
</DOC>